Categorization as a cytochrome P450 (CYP) 2C19 poor metabolizer (PM) is reported to be an independent risk factor for cardiovascular disease. Epoxyeicosatrienoic acids (EETs) are metabolites of arachidonic acid by CYP2C19 epoxygenases and anti-inflammatory properties, especially in microvascular tissues. We examined the association of CYP2C19 polymorphisms and EETs on microvascular angina (MVA) caused by coronary microvascular dysfunction. We examined CYP2C19 genotypes in patients with MVA (n ϭ 71) and healthy subjects as control (n ϭ 71). MVA was defined as the absence of coronary artery stenosis and epicardial spasms and the presence of inversion of lactic acid levels between intracoronary and coronary sinuses in acetylcholine-provocation test or the adenosine-triphosphate-induced coronary flow reserve ratio was below 2.5. CYP2C19 PM have two loss-of-functon alleles (*2, *3). We measured serum dihydroxyeicosatrienoic acid (DHET) as representative EET metabolite. MVA group showed significantly higher CYP2C19 PM incidence (35% vs. 16%; P ϭ 0.007) and high sense C-reactive protein (hs-CRP) levels (0.127 Ϯ 0.142 vs. 0.086 Ϯ 0.097 mg/dl; P ϭ 0.043) than those of controls. Moreover, in MVA group, hs-CRP levels in CYP2C19 PM were significantly higher than that of non-PM (0.180 Ϯ 0.107 vs. 0.106 Ϯ 0.149 mg/dl, P ϭ 0.045). Multivariate analysis indicated that smoking, hypertension, high hs-CRP, and CYP2C19 PM are predictive factors for MVA. In MVA group, DHET levels for CYP2C19 PM were significantly lower than that of non-PM [10.9 Ϯ 1.64 vs. 14.2 Ϯ 5.39 ng/ml, P ϭ 0.019 (11,12-DHET); 15.2 Ϯ 4.39 vs. 17.9 Ϯ 4.73 ng/ml, P ϭ 0.025 (14, 
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We examined the impact of CYP2C19 genotypes and epoxyeicosatrienoic acid (EET) on patients with microvascular angina (MVA). In results, the CYP2C19 poor metabolizer genotype may be a new candidate risk factor for MVA via EET.
MICROVASCULAR ANGINA (MVA) is caused by coronary microvascular dysfunction, which can arise from chronic inflammation (5, 22, 29) . Epoxyeicosatrienoic acids (EETs) have been suggested to be anti-inflammatory (25) and potent vasodilators in the canine coronary microcirculation (27) , raising the possibility that low levels of EETs may cause microvascular dysfunction in humans.
EETs are endothelium-derived hyperpolarizing factors (EDHFs) generated from metabolism of arachidonic acid by cytochrome P450 (CYP) 2C19 epoxygenases (4, 37) .
Endothelial hyperpolarization mediated by the opening of the potassium and calcium (KCa) channels is originally recognized as the important initiating step for EDH mediated vasodilation (8) . Node et al. (25) reported that EETs prevented leukocyte adhesion to the vascular wall by a mechanism involving inhibition of transcription factor, nuclear factor-B, and IB kinase. The inhibitory effects of EETs were independent of their membrane-hyperpolarizing effects, suggesting that these molecules play an important nonvasodilatory role in vascular inflammation. Thus EETs have been suggested to be anti-inflammatory properties (25) . Moreover, EETs act as potent vasodilators in canine coronary microcirculation (27) . Therefore, low levels of EETs may cause microvascular dysfunction via inflammation in humans.
CYP2C19 is expressed in human endothelial cells, and enzymatic activity varies according to the number of CYP2C19 loss-of-function (LOF) alleles (*2, *3). CYP2C19 poor metabolizers (PM) have two LOF alleles (*2/*2, *2/*3, or *3/*3), and non-PM have none or one LOF allele (*1/*1 , *1/*2, or *1/*3) (8, 31) . CYP2C19 plays an important role in metabolism of clopidogrel, and therefore previous studies that have shown a link between CYP2C19 PM and cardiovascular outcomes have been on patients treated with clopidogrel due to the inability of such patients to convert clopidogrel to its active form, especially in acute coronary syndrome (ACS) (2, 18) . However, recent data suggested that CYP2C19 variants are an independent risk factor for diabetic retinopathy (9) and coronary artery disease (CAD) (12) regardless of clopidgrel therapy in humans. Furthermore, Bertrand-Thiebault et al. (3) reported that the blood levels of inflammatory markers [interleuikin-6 and high sense C-reactive protein (hs-CRP)] were significantly increased in CYP2C19 PM.
Thus we examined the incidence and impact of CYP2C19 variants in MVA by measuring serum hs-CRP and dihydroxyeicosatrienoic acid (DHET) as representative EET metabolite in patients with MVA.
METHODS
Study population.
From April 2009 to January 2014, 1,336 consecutive, hemodynamically, and symptomatically stable patients with suspected angina were registered and underwent angiography in Kumamoto University Hospital. We excluded patients with possible heart failure (left ventricular ejection fraction Ͻ50%), previous diagnoses of CAD, left ventricular hypertrophy (defined as Ͼ12-mm left ventricular wall thickness in echocardiography), severe hypertension (HT; Ͼ160/110 mmHg), valvular heart disease, and malignant diseases. In addition, patients with elevated white blood cell counts (Ͼ9,000) and/or serum hs-CRP (Ͼ0.5 mg/dl) were excluded to avoid the potentially confounding effects of occult infection or other systemic inflammatory diseases on hs-CRP levels.
After filtering, 1,198 patients were enrolled in this study. Vasoactive drugs, including calcium-antagonists, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and nitrates were withdrawn at least 5 days before patients entered this study; sublingual nitroglycerin was withdrawn within 24 h before entering the study. Patients with HT were defined as Ͼ140/90 mmHg. Patients with diabetes mellitus (DM) were defined as those with a 2-h glucose tolerance test Ն200 mg/dl, a fasting glucose level Ն126 mg/dl, an HbA1c score Ն6.5%, physician-diagnosed diabetes and/or the use of diabetic medication, and chronic kidney disease (CKD) testing with an estimated glomerular filtration rate Ͻ60 ml/(min·1.73 m 2 ). Dyslipidemia (DLP) was defined as low-density lipoprotein Ͼ140 mg/dl, high-density lipoprotein Ͻ40 mg/dl, or triglyceride Ͼ150 mg/dl.
Patients with no history of chest pain and no cardiovascular disease who underwent medical examinations at the Kumamoto Health Care Center in 2,010 were used as healthy control subjects (n ϭ 471). Control data were adjusted by age and gender by a propensity score matching method (SPSS software, Version 21.0, IBM Institute) to MVA patients, and 71 subjects were used as the control.
All procedures will be conducted in accordance with the Declaration of Helsinki and its amendments. The study protocol has been approved by the human ethics committee of each institution and written informed consent was obtained from each patient or from the family of the patient.
Definition of MVA. All MVA cases experiencing chest pain and ischemic changes in the electrocardiogram (ECG) in the exercise stress test underwent cardiac catheterization. We defined the MVA was not only without epicardial spasm but also lactic acid levels between intracoronary and coronary sinuses in ACh-provocation test were increased or adenosine triphosphate-induced coronary flow reserve ratio (ATP-CFR) was below 2.5 if lactic acid levels were decreased ( Fig. 1) (5, 26) . The acetylcholine (ACh)-provocation test and measurement of the ATP-CFR ratio were conducted according to the Japanese Circulation Society guidelines (15a). Measuring ATP-CFR scores was also used to diagnose microvascular coronary dysfunction in nonobstructive CAD (19, 24) .
Intracoronary ACh-provocation test. The method of intracoronary ACh-provocation test was described in detail previously (1, 14, 16) . In brief, incremental doses (20, 50 , and 100 g) of ACh chloride were injected into the left coronary artery over a period of 30 s each, and CAG was performed 1 min after the start of each provocation. The doses of ACh were administered at 5-min intervals. Subsequently, 50 g of ACh were injected into the right coronary artery without the FloWire, followed by CAG. After the administration of intracoronary isosorbide mononitrate (ISDN) and CAG at an interval of 10 min, adenosine triphosphate (ATP; 150 g·kg Ϫ1 ·min Ϫ1 ) was administered via the central vein until maximal hyperemia was achieved for the calculation of ATP-CFR. ATP-CFR was calculated with the following formula: hyperemia average peak velocity (APV)/Post-ISDN APV (36) .
Angiographical identification of epicardial spasm. A positive finding for coronary spasm on CAG in the ACh test is defined as "transient, total, or subtotal occlusion (Ͼ90% stenosis) of a coronary artery." In addition, a definite diagnosis of vasospastic angina requires simultaneous signs or symptoms of myocardial ischemia (angina pain and ischemic ECG change).
Lactate measurement in ACh-provocation test. To assess myocardial ischemia on the basis of the detection of increased lactate production in the coronary circulation, paired blood samples were collected simultaneously from the aortic root (LAR) and the coronary sinus (LCS) by using a coronary sinus catheter at three time points: baseline, 1 min after delivery of 100 g of ACh via the left coronary artery, and after administration of ISDN. The lactate production ratio
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Obstructive coronary artery disease was calculated with the following formula: (LCS-LAR)/LAR ϫ 100 (%). Normally, the ratio is negative, and a positive value definitively indicates the occurrence of myocardial ischemia. Genotyping. Genomic DNA was extracted from whole blood using the DNA Extractor WB kit (Wako Pure Chemical Industries), using a modified version of the protocol described by Richards et al. (30) CYP2C19*2 (681GϾA) and *3 (636 GϾA) are thought to account for Ͼ99% of LOF alleles generating null-activity enzymes in the Japanese population (6, 20) . Therefore, subjects were divided according to their CYP2C19 genotypes into two groups: PM with two LOF alleles (*2/*2, *2/*3, or *3/*3), and non-PM, consisting of EM (extensive metabolizer) lacking CYP2C19*2 and CYP2C19*3 (CYP2C19*1/*1) and IM (intermediate metabolizer) with one LOF allele (*1/*2 or *1/*3).
11,12 and 14,15-DHET measurement in serum. We measured serum 11,12 and 14,15-DHET in MVA (n ϭ 34) and control patients (n ϭ 20) with agreement. Blood samples were collected simultaneously from the coronary sinus by using a coronary sinus catheter. DHET is a representative metabolite of soluble epoxide hydrolasemediated metabolism of EETs and reflects the levels of EET. Serum 11,12-and 14,15-DHET levels were measured using an ELISA kit (R&D Systems).
Mixture of 1.0 ml serum and 1.0 ml ethyl acetate was centrifuged at 2,000 rpm for 10 min. Upper organic phases were collected and evaporated to dryness with nitrogen gas. A dried sample was dissolved in 2 ml 20% KOH and incubated for 1 h at 50℃. Formic acid was added to adjust pH to 5.5 and then equal amount of ethyl acetate was applied and centrifuged at 2,000 rpm for 10 min at room temperature. The upper phase was collected and dried up again. We reconstituted collected sample with 20 l and then proceeded to the ELISA reaction.
Statistical analyses. Continuous variables are expressed as mean Ϯ SD and compared using an unpaired t-test or Mann-Whitney's U-test, as appropriate. Categorical variables were expressed as numbers or percentages and compared using the 2 -test or Fisher's exact test. Univariate and multivariate logistic regression analyses were performed to identify predictors of MVA. Univariate analysis for the development of MVA was performed including conventional age, gender, body mass index, and coronary risk factors (HT, DM, DLP, CKD, and smoking); hs-CRP; and CYP2C19 genotypes. Multivariate analysis was performed including these risk factors with P Ͻ 0.05. Odds ratios (ORs) and 95% confidence intervals (CIs) were determined from the logistic regression analyses. P Ͻ 0.05 was regarded as statistically significant. SPSS software, Version 21.0 (IBM Institute) was used for all statistical analyses.
RESULTS
Characteristics of subjects.
A total of 1,198 patients were enrolled in this study, and 303 patients were defined as nonobstructive coronary artery disease after initial coronary angiography (CAG). Finally, 71 patients were defined as having MVA after an ACh-provocation test, the measurement of lactate in the coronary circulation, and ATP-provocation ( Figs.  1 and 2) .
In the clinical characteristics of the MVA and control groups, the prevalence of the characteristics of current smoker and HT were significantly higher in the MVA group than that of control group (12.7 vs. 2.80%, P ϭ 0.028, 59.2 vs. 40.8%, P ϭ 0.029; Table 1 ). Fig. 2 . Cases of MVA. A: no coronary artery stenosis in angiography, no epicardial spasms, and have inversion of lactic acid levels between intracoronary and coronary sinuses in ACh-provocation test. B: no coronary artery stenosis in angiography, no epicardial spasms, and without inversion of lactic acid levels between intracoronary and coronary sinuses (no transcardiac lactate production) in ACh-provocation test and adenosine triphosphate-induced coronary flow reserve ratio (ATP-CFR) was below 2.5. The transcardiac lactate production ratio then becomes positive during coronary circulation. LER, lactate extraction ratio; Ao/ Cs, aortic root/coronary sinus; ISDN, intracoronary isosorbide mononitrate; FFR, fractional flow reserve; HSr, hyperemic stress resistance; HMR, hyperemic microvascular resistance. Figure 3 shows that the incidence rates of CYP2C19 genotypes (PM and non-PM) were 35.2 and 64.8%, respectively, in the MVA group and 15.5 and 84.5%, respectively, in the control group. The incidence of CYP2C19 PM is significantly higher in the MVA group than that of the control group (P ϭ 0.007).
The levels of hs-CRP were significantly higher in the MVA group than those of the control group (0.127 Ϯ 0.142 vs. 0.086 Ϯ 0.097 mg/dl, P ϭ 0.043; Fig. 4A ), especially with CYP2C19 PM (0.180 Ϯ 0.107 vs. 0.086 Ϯ 0.078 mg/dl, P ϭ 0.016). Moreover, in the MVA group, the level of hs-CRP with CYP2C19 PM was significantly higher than that of non-PM (0.180 Ϯ 0.107 vs. 0.106 Ϯ 0.149 mg/dl, P ϭ 0.045; Fig. 4B ).
The levels of serum 11,12 and 14,15-DHET in the MVA group were significantly higher than those of the control group [13.8 Ϯ 3.30 vs. 8.24 Ϯ 3.17 ng/ml, P Ͻ 0.001 (Fig. 5A) , 18.5 Ϯ 4.97 vs. 10.8 Ϯ 1.20 ng/ml, P Ͻ 0.001 (Fig. 5C)] . Moreover, in the MVA group, the levels of serum 11,12 and 14,15-DHET with CYP2C19 PM were significantly lower than that of non-PM [14.2 Ϯ 5.39 vs. 10.9 Ϯ 1.64 ng/ml, P ϭ 0.019 (Fig. 5B) ; 18.9 Ϯ 4.73 vs. 15.2 Ϯ 4.39 ng/ml, P ϭ 0.025 (Fig. 5D)] .
In multiple regression analysis for MVA, current smoker, HT, high levels of hs-CRP, and CYP2C19 PM have been shown to be associated with MVA development (OR 5.53, 95% CI 1.08 -28.2, P ϭ 0.040; OR 2.15, 95% CI 1.06 -4.40, P ϭ 0.032; OR 2.07, 95% CI 1.00 -4.25, P ϭ 0.048; OR 2.49, 95% CI 1.06 -5.85, P ϭ 0.036; Table 2 ).
DISCUSSION
Our results show that MVA is related to CYP2C19 PM and chronic inflammation, suggesting that insufficient upregulation of EET, a vasodilator in microcirculation, is one possible cause of MVA.
The ratio of CYP2C19 PM and the hs-CRP level were significantly higher in the MVA group than those in the control group. The decreased enzyme activity of CYP2C19 PM, which decreases the level of EETs, appears to lead to increased inflammation and impaired microcirculation. Measurement of 11,12-and 14,15-DHET levels revealed that EETs were significantly higher in the MVA group than compared with the control group, suggesting that the MVA group had impaired microcirculation that activated the EET defense mechanisms and led to higher EET levels. However, the low rate of increase in the MVA PM group suggests dysfunctional EET upregulation. These results are consistent with a link between the low EET increase associated with decreased enzyme activity and the expansion of inflammation and impaired microcirculation in the CYP2C19 PM group. The previous report of comparison between CAD and control (non-CAD) group suggested that EETs levels increase in the patients with CAD relative to control subjects (34) . On the other hand, the report in CAD group suggested that EETs levels decrease by stenosis progress (28) . Moreover, Spiecker et al. (32) reported low EET levels in a subgroup with decreased enzymatic activity by CYP2J2 genetic mutations compared with another subgroup with normal enzymatic activity by wild CYP2J2 genotype among the CAD patients. CAD is defined as the presence of epicardial organic stenosis in above studies, and the definition of MVA was different from the definition of MVA in this study; Fig. 3 . Prevalence of cytochrome P450 (CYP) 2C19 genotypes. The ratio of CYP2C19 poor metabolizer (PM) in the MVA group is significantly higher than that of the control group. Fig. 4 . Comparison of high sense C-reactive protein (hs-CRP) levels. A: comparison of the control and MVA groups. The mean hs-CRP level is significantly higher in the MVA group than that of the control group. B: comparison of CYP2C19 PM and non-PM in the control and MVA groups. The mean hs-CRP level in the MVA group was significantly higher than that of control group, especially for CYP2C19 PM. Moreover, in the MVA group, the mean hs-CRP level for CYP2C19 PM is significantly higher than that for non-PM. however, the lower EET levels in groups with LOF alleles (CYP2C19*2 and *3, CYP2J2*7) for patients with MVA or CAD suggest that EET has some effect in cases of epicardial or microcirculation.
Although there are several DHET isomers (8,9-DHET, 11,12-DHET, and 14,15-DHET) from EETs (7), we measured the levels of serum 11,12 and 14,15-DHET in this study. 11,12-DHET constitutes 24% of DHETs and 14,15-DHET are 39% (largest percentage) (17) . The same results were shown in not only 11,12-DHET but also 14,15-DHET, as reported previously (32, 33) .
In multivariate analysis (Table 2) , the risk factors for MVA were not only high levels of hs-CRP and CYP2C19 PM, but also current smoker and HT. It was reported that HT, diabetes mellitus, smoking status, dyslipidemia, insulin resistance, and obesity were reported as causes of microvascular dysfunction (5) . Moreover, Itoh et al. (15) reported that the spasm group has high ratio of smoker and HT. Spasm is defined by the presence of epicardial vasodilation; herein, as the definition of MVA was completely different, it is possible that the strong factors of endothelial dysfunction as HT and smoking are predicted as incidence of MVA.
Microvascular dysfunction was reportedly observed in ϳ20% of patients who complained of chest pain but who had no significant organic stenosis in the epicardial coronary artery (22) . In the present study, to define MVA, not only did we perform catheterization examinations in all the subjects but we also performed ACh-provocation testing, measurement of lactic acid, and ATP stress tests. Based on these results, we rigorously diagnosed the condition of the patients and obtained accurate results with no contradictions. From the group of patients in the present study who complained of chest pain and did not present with epicardial stenosis, MVA was diagnosed in ϳ23.4% of the patients, which was consistent with the rate reported by previous studies (22, 25) .
Limitations. This study has a small sample size. Because we performed both cardiac catheterization and ACh and ATP provocation tests for all enrolled subjects to define MVA, the definition of MVA in this study is more accurate than that in studies in which subjects are not subjected to ACh and ATP provocation tests. Second, we cannot be sure that CAD and microvascular dysfunction were absent in the control subjects because the control subjects did not undergo cardiac catheterization or ACh and ATP provocation tests. However, we chose individuals with no medical history of chest pain or cardiovascular disease as control subjects. Third, we have no information about medical therapy, especially concerning clopidogrel. We have no data about medication in the control group, so we cannot compare with the MVA group medication. However, there were no patients with clopidogrel therapy in MVA group and we chose individuals with no medical history of chest pain or cardiovascular disease as control subjects. Therefore, there is little influence on microvascular dysfunction of clopidogrel therapy in this study.
Fourth, we consider that it is desirable to measure EET, EET ϩ DHET, and EET/DHET ratio. In the present study, we used an ELISA kit, and it was difficult to measure EET concentration levels because preserved blood was hydrolyzed. We consider and discuss this study under the consideration that DHET is equal to EET; this consideration was also a study limitation. Finally, CYP2C19 PMs are present in 2-3% of Caucasians (21), whereas they are found in Ͻ20% of Asians, including Japanese subjects (11, 21, 23, 35) . The subjects in the present study were limited to Japanese because there is a racial difference in CYP2C19 genotype and thus the results of this study may not be necessarily applicable to other populations.
Clinical implications. The variant of CYP2C19 genotype was associated with MVA in the Japanese. This study thus identified reduced DHET, which reflects EET levels and hence an insufficient defensive mechanism as a risk factor to be targeted and intervened for the treatment and prevention of MVA. Recently, Iming et al. (13) showed that a novel molecule inhibitor of epoxide hydrolase (EH) inhibited the activity of EH and effectively restored the EET concentration in animal models. Accordingly, it is expected that this class of drug may serve as a new therapeutic for MVA in the future.
Conclusions. Our results indicate that CYP2C19 variants are associated with MVA. The decline of EET-based defensive mechanisms owing to CYP2C19 variants may affect coronary microvascular dysfunction.
